Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?

Hims & Hers (HIMS) stock has recently surged 64.1%, significantly outperforming industry peers and broader markets, driven by robust Q2 2025 top and bottom-line growth, increased subscribers, and operating margin expansion, despite a 491 basis point gross margin contraction due to rising product costs. The company is actively pursuing strategic initiatives including the launch of a new men's health category, aggressive international expansion through the ZAVA acquisition and planned Canadian entry, and a $870 million convertible notes offering to fund global growth and AI-driven personalization under a new CTO. While 2025 EPS estimates have seen a downward revision, HIMS projects strong FY2025 revenue growth of 56-63% to $2.3B-$2.4B, indicating continued operational momentum and a favorable long-term outlook despite valuation concerns relative to its historical median.

Analysis

Hims & Hers Health (HIMS) is exhibiting strong operational momentum and significant stock price appreciation, with a 64.1% gain over the past six months that substantially outperforms the industry, the S&P 500, and telehealth peers like Teladoc Health (TDOC) and Amwell (AMWL). This performance is underpinned by robust second-quarter 2025 results, which saw an increase in subscribers and monthly online revenue per subscriber, driving top and bottom-line growth. Management has issued confident full-year 2025 revenue guidance of $2.3 to $2.4 billion, representing 56-63% year-over-year growth. This aggressive growth strategy is fueled by key initiatives, including international expansion via the acquisition of European platform ZAVA, a planned 2026 entry into Canada, and product innovation with the launch of an oral testosterone therapy. The company has secured an upsized $870 million in convertible senior notes to fund these ambitions. However, significant risks temper this outlook. Gross margin contracted by 491 basis points in the second quarter due to rising product costs, and 2025 consensus earnings estimates have been revised downward by 17.8% over the past 60 days. While its forward P/S ratio of 4.4X is below the industry average of 6.1X, it is substantially higher than its three-year median of 2.4X and its direct peers, indicating that high growth expectations are already priced in.

Key Decisions for Investors

• Investors should closely monitor gross margin trends and cost of revenues, as the recent 491 basis point contraction and the 17.8% downward revision in 2025 EPS estimates represent the primary risk to the company's profitability narrative.
• Given the stock's 64.1% run-up, continued outperformance is heavily dependent on successful execution of its strategic initiatives, particularly the integration of the ZAVA acquisition in Europe and the market adoption of new products like oral testosterone therapy.
• While the forward P/S multiple of 4.4x appears favorable relative to the industry, it represents a significant premium over its historical median and peers, suggesting investors should weigh the aggressive growth outlook against execution risks and the potential for valuation multiple compression if growth moderates or margin issues persist.